secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2024-03-29T23:59:59+00:00
Accession:  0001104659-24-041200
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance Biotherapeutics director McPeak to retire; interim CEO Vogt nominated to board
--------------------------------------------------------------------------------

- Director Merrill A. McPeak to retire and not stand for re-election at June 2024 annual meeting.
- Frederick G. Vogt, Interim CEO and General Counsel, nominated to fill the vacancy.
- Board unanimously adopted Fourth Amended and Restated Bylaws redefining 'Acting in Concert'.
- McPeak's retirement is not due to any disagreement with the Company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465924041200/0001104659-24-041200-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465924041200/tm2410183d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-041200

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer